Biotech Startup Nuritas Raises €16 Million to ‘unlock bioactive peptides’

By Lucy Whitehouse

- Last updated on GMT

Biotech Startup Nuritas Raises €16 Million to ‘unlock bioactive peptides’

Related tags Investment Artificial intelligence

Nuritas has announced that it recently closed a €16M Series A funding round aimed to support its innovation in the area of peptides for personal care and health applications.

The Dublin-based biotech company is working on the discovery and use of bioactive peptides through artificial intelligence (AI) and genomics.

It says that the latest funding round, led by Chicago-based Cultivian Sandbox Ventures, sees the total invested in the startup to date to approximately €25 million, including early funding from well-known figures Bono (U2), and Salesforce’s CEO Marc Benioff.

The latest round of funding will support Nuritas’ global growth, says the company, with the biotech player aiming to “address and solve many of the most pressing health issues of the day, including the diabetes epidemic​”.

Investing in growth

The company is tipped to grow rapidly, with the latest investment set to boost this.

Nuritas’ unique platform delivers truly life-changing health benefits and we are very pleased to be involved in its growth – it’s a brilliant team and such an exciting technology,​” said Nick Rosa, Managing Director of Cultivian Sandbox and Co-founder of Sandbox Industries, which led the latest funding series.

We expect Nuritas to quickly emerge as one of the most innovative companies in the world, effecting real change.​”

Health focus

Nuritas Founder and Chief Scientific Officer Dr Nora Khaldi explained that moving forward, health applications for its research and innovation will be a primary focus.

This investment will not only help us accelerate our route to market, explore new disease areas and grow our already strong team, but it will also push us even further in extracting the great potential of what our technology is capable of creating,​” says Khaldi.

What is so exciting is that the inflammation ingredient launching in the U.S. next year is actually the first healthcare ingredient that has been fully discovered through the use of Artificial intelligence.”

Related news

Related products

show more

Calendula Cellular Elixir: Alchemy in a cell

Calendula Cellular Elixir: Alchemy in a cell

Content provided by Naolys | 24-Apr-2024 | Product Brochure

Get ready to experience a cellular evolution in skincare with InnerLift Calendula's advanced Plant Cell biotechnology.

See our latest innovations in personal care

See our latest innovations in personal care

Content provided by Covation Bio™ PDO | 02-Apr-2024 | White Paper

At CovationBio PDO, we’re helping the world achieve its sustainability goals by enabling better performing, better-for-the planet products across a range...

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers

Follow us

Products

View more

Webinars

Podcast

Beauty 4.0 Podcast